You are here:Home-Chemical Inhibitors & Agonists-Tyrosine Kinase-FLT3-HSN748
HSN748

Chemical Structure : HSN748

CAS No.: 2409925-53-5

HSN748 (HSN 748, HSN-748)

Catalog No.: PC-22539Not For Human Use, Lab Use Only.

HSN748 is potent, selective, type II inhibitor of FLT3 (Kd=0.15 nM) and FLT3 mutants (FLT3 D835Y, KD=1.4 nM), shows potently effective against drug-resistant secondary mutations of FLT3.

Packing Price Stock Quantity
50 mg Get quote
100 mg Get quote
250 mg Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC)

Biological Activity

HSN748 is potent, selective, type II inhibitor of FLT3 (Kd=0.15 nM) and FLT3 mutants (FLT3 D835Y, KD=1.4 nM), shows potently effective against drug-resistant secondary mutations of FLT3.
HSN748 preferentially binds the nonphosphorylated form of ABL (dissociation constant, or Kd = 0.29 nM) compared with the phosphorylated (active) enzyme (Kd = 0.74 nM).
HSN748 inhibits a panel of clinically relevant FLT3 mutations, including FLT3ITD–F691L and FLT3ITD–D835Y, with Kd in the sub-to-low nanomolar range with the exception of FLT3ITD–D835Y.
HSN748 potently inhibits cell growth of murine BaF3 cells expressing FLT3ITD (IC50=0.04 nM), FLT3ITD–F691L (gatekeeper mutation, IC50=1.52 nM), and FLT3ITD–D835Y (activation loop mutation).
HSN748 is superior in inhibiting FLT3 mutant–driven cell lines compared with all other FLT3 inhibitors tested in vitro.
HSN748 exhibits inhibitory effect on the tumor growth and survival advantage of MOLM14 and MOLM14-FLT3ITD–F691L-recipient mice.
HSN748 shows antileukemic activity against FLT3ITD in drug-resistant AML, relapsed/refractory AML, and in AML bearing a combination of epigenetic mutations of TET2 along with FLT3ITD.

Physicochemical Properties

M.Wt 519.53
Formula C27H24F3N7O
Appearance Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

5-(imidazo[1,2-b]pyridazin-3-ylethynyl)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)nicotinamide

References

1. Baskar Ramdas, et al. J Clin Invest. 2024 Jun 17;134(12):e169245.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: